{"id":"20969f5cf248","type":"article","url":"https://hartvaat.nl/2026/10/24/biomarkergestuurd-screening-en-multidisciplinaire-zorg-verlagen-risico-op-hartfa/","title":"Biomarkergestuurd screening en multidisciplinaire zorg verlagen risico op hartfalen — JHFV Scientific Statement","title_en":"Practical Prevention of Heart Failure Across Stages A and B: A Scientific Statement From the Japanese Heart Failure Society.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Journal of cardiac failure","doi":"10.1016/j.cardfail.2026.09.036","source_url":"https://doi.org/10.1016/j.cardfail.2026.09.036","authors":["Sho Suzuki","Hideo Izawa","Koichiro Kuwahara","Yasuhiko Sakata","Katsuya Onishi","Yukiko Okada","Takahiro Okumura","Yukihito Sato","Akinori Sawamura","Akihisa Hanatani","Tomoyuki Kunishima","Masanari Kuwabara","Takayuki Inomata","Koichiro Kinugawa"],"significance":6,"published":"2026-11-02","source_date":"2026-10-24","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/sglt2-remmers-bij-diabetes-hartaandoeningen/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"The Japanese Heart Failure Society issues a scientific statement outlining practical prevention strategies for heart failure in asymptomatic stages A and B. The guidance emphasizes biomarker-driven screening with BNP/NT-proBNP, aggressive management of cardiorenal-metabolic risk factors, and structured referral pathways between primary care, internal medicine, and cardiology. Implementing these coordinated preventive measures can delay progression to symptomatic heart failure and enable earlier therapeutic intervention, making it a valuable framework for multidisciplinary teams.","created":"2026-10-26T02:32:25Z","updated":"2026-10-26T02:32:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De Japanse Hartfalen Vereniging publiceert een wetenschappelijke statement over praktische preventiestrategieën voor hartfalen in de vroege stadia A en B. Centraal staat biomarkergestuurd screening met BNP/NT-proBNP, intensieve risicofactormanagement (hypertensie, diabetes, nierfunctie, obesitas) en duidelijke verwijspaden tussen cardiologen en niet-cardiologen. Deze gestructureerde aanpak kan helpen om progressie naar symptoomhartfalen te vertragen en vroegtijdige interventie te faciliteren, wat vooral relevant is voor zorg in de eerste lijn en de interne geneeskunde.","abstract_original":"Heart failure (HF) is a growing health problem in Japan, associated with substantial morbidity, mortality, recurrent hospitalization, impaired quality of life, and increasing healthcare costs. Early prevention before the onset of signs and symptoms has therefore become a major priority in cardiovascular medicine. This scientific statement from the Japanese Heart Failure Society provides practical prevention strategies for patients with HF Stage A and Stage B in Japan. Particular emphasis is placed on biomarker-guided screening using brain (B-type) natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) to facilitate earlier detection of Stage B (pre-HF) and identification of patients at increased risk of progression to symptomatic HF. The statement summarizes evidence-based management of major cardiovascular-kidney-metabolic disorders associated with HF development, including hypertension, diabetes mellitus, chronic kidney disease, obesity, coronary artery disease, left ventricular dysfunction, valvular heart disease, and atrial fibrillation. It also addresses disease-specific approaches for optimizing blood pressure, glycemic control, renal protection, lipid management, and weight reduction. Preventive strategies include lifestyle modification, pharmacological therapy, serial reassessment of natriuretic peptide levels, and appropriate use of cardiovascular imaging and timely specialist referral. Because many patients at risk for HF are managed outside specialized cardiovascular centers, practical pathways for collaboration between cardiologists and non-cardiologist physicians are essential. The importance of timely referral, shared risk recognition, and multidisciplinary care is therefore emphasized. Implementation of clinically applicable prevention strategies may help reduce progression to symptomatic HF, facilitate earlier therapeutic intervention, and improve long-term cardiovascular outcomes."}